Home › Funds › Paradigm Biocapital Advisors LP › COAG
Paradigm Biocapital Advisors LP position in COAG
HEMAB THERAPEUTICS HLDGS INC · Health Care
Paradigm Biocapital Advisors LP reported holding 629,347 shares of COAG (HEMAB THERAPEUTICS HLDGS INC) in its Q3 2026 13F filing — a position valued at US$19.4M, representing 0.39% of its reported portfolio and ranking #25 among its reported holdings. Paradigm Biocapital Advisors LP first reported this position in Q3 2026.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How Paradigm Biocapital Advisors LP's COAG position evolved
Paradigm Biocapital Advisors LP first disclosed a stake in COAG in Q3 2026 at 629,347 shares (US$19.4M).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2026 | 629.35K | $19.41M | New |
About COAG and 13F data
COAG (HEMAB THERAPEUTICS HLDGS INC) is a Health Care company. 85 other funds we track also report a position in COAG — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$286.8M), Novo Holdings A/S (US$153.6M), Deep Track Capital, LP (US$110.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding COAG
- RA CAPITAL MANAGEMENT, L.P. 7.81M sh · $286.81M · Q2 2026
- Novo Holdings A/S 4.18M sh · $153.55M · Q2 2026
- Deep Track Capital, LP 3.59M sh · $110.65M · Q3 2026
- Siren, L.L.C. 2.37M sh · $72.97M · Q3 2026
- Avoro Capital Advisors LLC 1.89M sh · $58.36M · Q3 2026
- Bain Capital Life Sciences Investors, LLC 1.65M sh · $50.89M · Q3 2026
- Rock Springs Capital Management LP 575.43K sh · $17.75M · Q3 2026
- Affinity Asset Advisors, LLC 420.00K sh · $12.95M · Q3 2026
- Parkman Healthcare Partners LLC 329.25K sh · $10.15M · Q3 2026
- Opaleye Management Inc. 47.65K sh · $1.75M · Q2 2026
More on Paradigm Biocapital Advisors LP
FAQ
How long has Paradigm Biocapital Advisors LP held COAG?
Paradigm Biocapital Advisors LP has disclosed COAG holdings in 1 of the last 1 reported quarters, going back to Q3 2026.
What is Paradigm Biocapital Advisors LP's current position in COAG?
As of Q3 2026, Paradigm Biocapital Advisors LP holds 629.35K shares of COAG (HEMAB THERAPEUTICS HLDGS INC), valued at $19.41M, representing 0.39% of its reported portfolio and ranking #25.
Has Paradigm Biocapital Advisors LP been buying or selling COAG?
In the latest 13F filing (Q3 2026), Paradigm Biocapital Advisors LP newly opened its position in COAG.
Which other funds hold COAG?
Other major institutional holders of COAG include RA CAPITAL MANAGEMENT, L.P., Novo Holdings A/S, Deep Track Capital, LP, among 85 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.